39 related articles for article (PubMed ID: 31232278)
21. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.
Medellin-Garibay SE; Hernández-Villa N; Correa-González LC; Morales-Barragán MN; Valero-Rivera KP; Reséndiz-Galván JE; Ortiz-Zamudio JJ; Milán-Segovia RDC; Romano-Moreno S
Cancer Chemother Pharmacol; 2020 Jan; 85(1):21-31. PubMed ID: 31673826
[TBL] [Abstract][Full Text] [Related]
23. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.
Zhang C; Zhai S; Yang L; Wu H; Zhang J; Ke X
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):11-21. PubMed ID: 20040335
[TBL] [Abstract][Full Text] [Related]
25. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia
.
Zang YN; Wang SZ; Qin Y; Zhang JR; Zhao LB; Wang XL
Int J Clin Pharmacol Ther; 2019 Aug; 57(8):402-407. PubMed ID: 31232278
[TBL] [Abstract][Full Text] [Related]
27. Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?
Evans WE; Relling MV; Boyett JM; Pui CH
Leuk Res; 1997 May; 21(5):435-7. PubMed ID: 9225072
[No Abstract] [Full Text] [Related]
28. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.
Reddick WE; Glass JO; Helton KJ; Langston JW; Xiong X; Wu S; Pui CH
AJNR Am J Neuroradiol; 2005 May; 26(5):1263-9. PubMed ID: 15891195
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review.
Yang Y; Liu Z; Chen J; Wang X; Jiao Z; Wang Z
Eur J Clin Pharmacol; 2024 Jan; 80(1):11-37. PubMed ID: 37934204
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]